Trevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on Wednesday

Trevi Therapeutics (NASDAQ:TRVI) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Trevi Therapeutics to post earnings of ($0.12) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter last year, the business posted ($0.07) EPS. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Trading Up 2.4 %

Shares of NASDAQ TRVI opened at $3.01 on Monday. The stock has a fifty day moving average price of $3.15 and a 200 day moving average price of $2.90. The company has a market cap of $218.50 million, a P/E ratio of -7.72 and a beta of 1.01. Trevi Therapeutics has a 12-month low of $0.97 and a 12-month high of $4.00.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TRVI. B. Riley restated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Raymond James assumed coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price target for the company. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, October 22nd. Leerink Partners assumed coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday, October 4th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $7.43.

Insider Buying and Selling

In related news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas Sciascia sold 18,660 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,355 shares of company stock worth $116,663 over the last ninety days. 24.37% of the stock is owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.